Clinical Trial Update: Comparison of LY686017 With a Marketed Drug in the Treatment of Social Anxiety Disorder [Phase 2]

View source ↗

Summary

This document reports Phase 2 results from a head-to-head trial comparing the investigational LY686017 with a marketed comparator in social anxiety disorder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Social Anxiety Disorder

Drugs mentioned

• LY686017
• Unspecified marketed comparator

Snippet

Sponsor: Eli Lilly and Company | Conditions: Social Phobia | Phase 2 | Status: COMPLETED